Aprepitant - Generic Drug Details

« Back to Dashboard

What are the generic sources for aprepitant and what is the scope of patent protection?

Aprepitant is the generic ingredient in four branded drugs marketed by Glenmark Speclt, Sandoz, Torrent, MSD, Heron Theraps Inc, Azurity, Mylan, and Msd Merck Co, and is included in nine NDAs. There are fifteen patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for aprepitant

International Patents:	57
US Patents:	15
Tradenames:	4
Applicants:	8
NDAs:	9
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	186
Patent Applications:	4,261
Drug Prices:	Drug price trends for aprepitant
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aprepitant
What excipients (inactive ingredients) are in aprepitant?	aprepitant excipients list
DailyMed Link:	aprepitant at DailyMed

See drug prices for aprepitant

Recent Clinical Trials for aprepitant

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Montefiore Medical Center	PHASE4
Centre hospitalier de l'Universit de Montral (CHUM)	PHASE3
Rabin Medical Center	PHASE1

See all aprepitant clinical trials

Generic filers with tentative approvals for APREPITANT

Applicant	Application No.	Strength	Dosage Form
		130MG/18ML	INJECTION, EMULSION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for aprepitant

Drug Class	Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Cytochrome P450 2C9 Inducers Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for aprepitant

A04AD	Other antiemetics
A04A	ANTIEMETICS AND ANTINAUSEANTS
A04	ANTIEMETICS AND ANTINAUSEANTS
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for APREPITANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
APONVIE	Intravenous Emulsion	aprepitant	32 mg/4.4 mL	216457	1	2023-11-07
CINVANTI	Intravenous Emulsion	aprepitant	130 mg/18 mL	209296	1	2022-04-29
EMEND	for Oral Suspension	aprepitant	125 mg/Kit	207865	1	2016-11-23
EMEND	Capsule	aprepitant	40 mg, 80 mg and 125 mg	021549	1	2008-11-03

US Patents and Regulatory Information for aprepitant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes			Y
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes			Y
Torrent	APREPITANT	aprepitant	CAPSULE;ORAL	211835-001	Oct 21, 2020	AB	RX	No	No
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes
Azurity	APREPITANT	aprepitant	EMULSION;INTRAVENOUS	218754-001	Jun 16, 2026		RX	Yes	Yes
Heron Theraps Inc	APONVIE	aprepitant	EMULSION;INTRAVENOUS	216457-001	Sep 16, 2022		RX	Yes	Yes
Glenmark Speclt	APREPITANT	aprepitant	CAPSULE;ORAL	207777-003	Oct 12, 2017	AB	RX	No	No

Expired US Patents for aprepitant

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-001	Mar 26, 2003
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-003	Jun 30, 2006
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-002	Mar 26, 2003
Msd	EMEND	aprepitant	CAPSULE;ORAL	021549-002	Mar 26, 2003

EU/EMA Drug Approvals for aprepitant

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp & Dohme B.V.	Emend	aprepitant	EMEA/H/C/000527Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy.	Authorised	no	no	no	2003-11-11

International Patents for aprepitant

Country	Patent Number	Title	Estimated Expiration
China	106852118
European Patent Office	3193830
Japan	2017533183
Japan	2019196398
Japan	2022092040
Japan	6741655
South Korea	102424837

Supplementary Protection Certificates for aprepitant

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0734381	04C0010	France		PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
0734381	PA2004002,C0734381	Lithuania		PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
0748320	08C0019	France		PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
0734381	SPC/GB04/011	United Kingdom		PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
0748320	SPC/GB08/021	United Kingdom		PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
0734381	3/2004	Austria		PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
0734381	PA2004002	Lithuania		PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111

Aprepitant Market Dynamics, Patent Expiration, Generic Competition, and Financial Trajectory

Last updated: October 25, 2026

Aprepitant has moved from a branded antiemetic franchise to a mature, multi-source generic market. Merck’s Emend franchise generated substantial revenue during the 2000s and early 2010s, but core patent expiry, generic capsule approvals, competing neurokinin-1 therapies, and hospital purchasing pressure materially reduced branded economics. The commercial opportunity now centers on generic supply, injectable formulations, oncology-channel contracts, and differentiated delivery systems rather than broad product exclusivity.

What is the commercial status of aprepitant?

Aprepitant is an oral neurokinin-1, or NK1, receptor antagonist used to prevent acute and delayed chemotherapy-induced nausea and vomiting. Its principal branded product was Emend, marketed by Merck. The injectable prodrug fosaprepitant was marketed as Emend for Injection.

Product	Active ingredient	Dosage form	Principal commercial role
Emend	Aprepitant	Oral capsules	Original branded oral product
Generic aprepitant	Aprepitant	Oral capsules	Mainstream generic replacement
Emend for Injection	Fosaprepitant	Intravenous powder	Hospital and infusion-center use
Cinvanti	Aprepitant	Injectable emulsion	Alternative IV formulation
Akynzeo	Netupitant/palonosetron	Oral fixed-dose combination	Competing NK1 and 5-HT3 product
Varubi	Rolapitant	Oral tablets and injection	Competing NK1 product

The clinical value of aprepitant is strongest in highly emetogenic chemotherapy regimens, where guidelines generally use an NK1 antagonist with a 5-HT3 antagonist and dexamethasone. The addressable market is therefore linked to oncology treatment volume, chemotherapy intensity, antiemetic guideline compliance, and shifts toward oral or outpatient care.

How has the aprepitant market evolved?

The market passed through four commercial phases.

Branded launch and rapid adoption

Merck launched Emend in the United States in 2003 after FDA approval for prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy. Aprepitant was one of the first commercially important NK1 antagonists and gained adoption through inclusion in major antiemetic protocols (U.S. Food and Drug Administration, 2003).

Expansion into moderate-emetogenic chemotherapy

The product expanded beyond highly emetogenic chemotherapy. Broader guideline use increased prescription volume, but it also made the product more exposed to payer management and lower-cost alternatives.

Patent-cliff transition

The loss of core U.S. patent protection allowed generic manufacturers to enter the oral capsule market. Emend revenue declined as hospitals, oncology practices, and pharmacies shifted toward generic aprepitant.

Mature generic and injectable market

The current market is characterized by multiple suppliers, limited brand pricing power, and continued demand for injectable products. Cinvanti and fosaprepitant compete in settings where intravenous administration, excipient selection, or formulary preference matters.

What was the financial trajectory of Emend and aprepitant?

Merck reported Emend as a material pharmaceutical product during the franchise’s peak period. The product’s sales trajectory followed the standard pattern for a specialty drug with strong early adoption and a later patent cliff:

Period	Financial direction	Main driver
2003-2007	Rapid growth	Launch adoption and expansion into chemotherapy protocols
2008-2013	High-value branded maturity	Broad guideline use and limited direct generic pressure
2014-2016	Decline begins	Patent expiry expectations and generic preparation
2017-2019	Accelerated erosion	Generic oral aprepitant and competing NK1 products
2020 onward	Mature generic economics	Low-cost oral supply and injectable competition

Merck’s annual reports show Emend transitioning from a major growth product to a declining product as generic competition developed. Merck’s disclosed product reporting did not provide a complete global revenue series for every aprepitant formulation or third-party generic. As a result, current market value is better assessed through prescription volume, generic pricing, injectable utilization, and hospital contracts than through the historical branded-sales peak (Merck & Co., Inc., 2008, 2016, 2019).

The key financial distinction is between branded product revenue and molecule-level market revenue. Branded Emend revenue fell sharply after generic entry, but total spending on aprepitant did not disappear. It shifted to generic manufacturers, wholesalers, hospital purchasing groups, and alternative formulations.

When did aprepitant lose exclusivity?

Core composition and use patents protecting aprepitant and its antiemetic use expired in the United States during the second half of the 2010s, subject to patent-specific extensions and regulatory exclusivity provisions.

Exclusivity category	Commercial effect
Core aprepitant composition patents	Protected the original molecule and delayed direct generic substitution
Method-of-use patents	Covered use in chemotherapy-induced nausea and vomiting and related dosing protocols
Formulation patents	Created narrower protection for injectable or specialized dosage forms
FDA new-drug exclusivity	Supported early branded commercialization before broad generic approval
Pediatric exclusivity	Could extend selected patent or exclusivity periods by six months

The original Emend patent estate no longer provides broad market exclusivity for ordinary oral aprepitant capsules. Current protection is narrower and depends on the specific formulation, dosage form, manufacturing process, or labeled use listed in the FDA Orange Book.

What patents protect aprepitant?

The original U.S. patent estate included composition-of-matter and therapeutic-use protection associated with aprepitant and related NK1 antagonists. Important historical patent families included U.S. patents such as U.S. Patent No. 5,691,336 and related continuation or divisional filings assigned to or associated with Merck.

Patent protection generally covered:

1. The aprepitant chemical compound.
2. Pharmaceutical compositions containing aprepitant.
3. Treatment of nausea and vomiting associated with chemotherapy.
4. Specific dosing schedules.
5. Injectable prodrug or formulation technology for fosaprepitant.
6. Stability, excipient, and delivery characteristics for later injectable products.

The commercial importance of these categories differs materially. A composition patent can block all ordinary versions of the molecule. A method-of-use patent is narrower because an abbreviated new drug application may use a carve-out label. A formulation patent can remain relevant for an injectable product even after oral composition patents expire.

What formulations are protected by aprepitant patents?

The main formulation distinction is between oral aprepitant and injectable products.

Oral capsules became vulnerable to generic competition after expiration of broad compound and use protection. Injectable products have a more complex patent and regulatory profile because they require control of solubility, precipitation, excipient compatibility, stability, particulate matter, and container closure.

Fosaprepitant is a water-soluble prodrug of aprepitant designed for intravenous administration. Cinvanti uses an injectable emulsion formulation of aprepitant rather than the fosaprepitant prodrug. This creates a separate technical and competitive pathway.

Formulation protection has commercial value where it creates a substitutable, reimbursable product with fewer administration barriers. It is less valuable when hospitals view products as therapeutically interchangeable and procurement is driven by contract price.

What is the FDA and Orange Book status of aprepitant?

FDA-approved aprepitant products include oral capsules and injectable products. The branded Emend capsule franchise is no longer the sole FDA-approved source of aprepitant in the United States.

Regulatory issue	Status
Original Emend oral approval	Approved in 2003
Generic oral aprepitant	Approved through ANDA pathway
Fosaprepitant injection	Approved as an IV product
Cinvanti injectable emulsion	Approved in 2017
Orange Book relevance	Lists patents and exclusivity for eligible FDA-approved products
Biosimilar pathway	Not applicable because aprepitant is a small molecule

The Orange Book remains relevant for listed formulation and method-of-use patents, but it does not preserve the original broad exclusivity of Emend. Generic applicants can use paragraph IV certifications against listed patents or use section viii labeling carve-outs for protected indications.

Which companies challenged or replaced Emend?

Generic competition came from manufacturers filing abbreviated new drug applications for aprepitant capsules. Major generic companies active across the product category have included Teva, Dr. Reddy’s Laboratories, Sandoz, Glenmark, Zydus, and other FDA-approved suppliers, although participation varies by strength, dosage form, and period.

The competitive landscape has three layers:

Generic oral aprepitant

This is the largest source of price pressure. Multiple manufacturers can supply the same capsule strengths, and pharmacy benefit managers can move volume rapidly between suppliers.

Injectable fosaprepitant

Fosaprepitant competes for hospital and infusion-center demand. The product has a higher technical barrier than oral capsules because sterile manufacturing and injectable quality requirements limit the supplier base.

Alternative NK1 products

Akynzeo combines netupitant with palonosetron. Rolapitant has competed in the same broad antiemetic category. These products may preserve branded pricing where combination convenience, guideline positioning, or contracting offsets the cost of generic aprepitant.

Are there biosimilar risks for aprepitant?

There is no biosimilar risk because aprepitant is a chemically synthesized small-molecule drug. The relevant competitive pathway is generic substitution under the ANDA system.

The risk profile differs by product:

Product type	Main competitive risk
Oral aprepitant capsule	High generic substitution and price erosion
Fosaprepitant injection	Moderate supplier and contracting pressure
Aprepitant injectable emulsion	Formulation-specific competition and hospital formulary control
Fixed-dose NK1 combinations	Therapeutic substitution rather than direct generic substitution

What generic launch scenarios exist for aprepitant?

The most likely commercial scenarios are:

1. Continued low-price erosion in oral capsules as suppliers compete for commodity volume.
2. Periodic shortages or supplier exits because low margins reduce inventory incentives.
3. Stable hospital demand for injectable products where administration occurs in controlled oncology settings.
4. Increased use of combination antiemetic products when adherence or protocol simplification has economic value.
5. Greater contracting pressure from group purchasing organizations and integrated delivery networks.

Generic entry does not eliminate revenue opportunities. It changes the economics from brand promotion to manufacturing scale, reliable supply, regulatory compliance, and channel access.

What manufacturing and intellectual-property barriers remain?

The principal barriers are technical and operational rather than broad composition-patent barriers.

For oral aprepitant, manufacturing is comparatively accessible. Competitive advantage depends on cost, quality systems, approved strengths, capacity utilization, and distribution.

For injectable products, barriers include:

• Sterile filling capability.
• Control of particle size and emulsion stability.
• Excipient compatibility.
• Container-closure integrity.
• Low particulate burden.
• Validated aseptic processing.
• Reliable supply of active pharmaceutical ingredient.
• FDA inspection and manufacturing compliance.

The injectable market is more defensible than the oral capsule market, but it remains exposed to contract pricing and hospital substitution.

What patent litigation and settlement issues affect aprepitant?

Aprepitant’s principal litigation risk was concentrated around generic challenges to the original Emend patent estate. As core patents expired and generic approvals became widespread, the strategic importance of new paragraph IV litigation declined.

Current litigation risk is more likely to arise from:

• Later-filed injectable formulation patents.
• Manufacturing-process patents.
• Labeling disputes involving chemotherapy indications.
• ANDA patent certifications.
• Contract and supply disputes.
• Product liability or manufacturing-quality claims.

Publicly disclosed settlements involving historical Emend challenges are less important to present-day valuation than the expiration of broad composition protection and the number of approved generic suppliers.

How does aprepitant compare with competing antiemetics?

Factor	Aprepitant	Fosaprepitant	Netupitant/palonosetron	Rolapitant
Route	Oral	IV	Oral	Oral or IV, depending on product
Commercial maturity	Mature generic	Mature injectable	Branded combination	Smaller competing franchise
Price pressure	High	Moderate	Lower than generic aprepitant	Product-specific
Main advantage	Established efficacy and low cost	IV administration and protocol fit	Combination convenience	Long-acting NK1 activity
Main weakness	Commodity pricing	Sterile manufacturing cost	Brand premium	Limited scale and competition

Aprepitant retains a strong position because clinicians know the molecule, guidelines support NK1 therapy, and generic pricing lowers treatment cost. Its weakness is limited differentiation in the oral capsule market.

How strong is the aprepitant patent estate?

The estate is weak for ordinary oral aprepitant capsules and stronger for selected injectable formulations.

Segment	Patent strength	Commercial interpretation
Original oral molecule	Expired or commercially exhausted	Generic substitution established
Oral method of use	Narrow	Carve-outs and label limitations reduce blocking power
Fosaprepitant injection	Moderate historical protection	Sterile manufacturing and formulation complexity matter
Aprepitant injectable emulsion	Product-specific	Protection depends on listed patents and formulation scope
Manufacturing methods	Variable	Can delay specific entrants but rarely restores broad monopoly economics

What is the revenue exposure from aprepitant?

For Merck, aprepitant became a declining franchise rather than a material long-term growth driver. Revenue exposure shifted after generic entry from a high-margin branded product to a fragmented market.

For current manufacturers, value depends on:

• Number of approved competitors.
• Contracted hospital volume.
• Wholesale acquisition price.
• Reimbursement and substitution rules.
• Manufacturing yield.
• Supply reliability.
• Product-specific regulatory exclusivity.

Investors should not value generic oral aprepitant using the historical peak sales of Emend. Injectable products and combination regimens require separate volume and margin assumptions.

Key Takeaways

• Aprepitant is a mature generic antiemetic market, not an active broad-exclusivity brand market.
• Merck’s Emend franchise experienced substantial revenue erosion after oral generic entry.
• Core composition protection has expired or lost practical commercial force.
• Oral aprepitant has high generic competition and limited pricing power.
• Fosaprepitant and injectable aprepitant have higher manufacturing barriers than capsules.
• Biosimilar risk is irrelevant; ANDA-based generic competition is the key risk.
• Current commercial value rests on supply reliability, hospital contracts, sterile manufacturing, and formulation differentiation.
• Competing NK1 products can retain branded value through combination dosing or protocol convenience.
• The strongest remaining intellectual-property positions are product-specific formulation and manufacturing claims rather than broad molecule claims.

FAQs

Is aprepitant still a profitable drug?

Generic oral aprepitant is usually a low-margin, high-volume product. Injectable formulations can support better economics because sterile manufacturing and hospital contracts create higher entry barriers.

Is Emend still protected by patents?

Broad protection for ordinary oral aprepitant has expired or no longer provides practical market exclusivity. Narrow formulation and method-of-use patents may remain relevant for specific products.

Can a generic manufacturer launch aprepitant without challenging every patent?

Yes. An ANDA applicant can use a paragraph IV certification, a section viii carve-out, or wait for expiration of relevant listed patents, depending on the product and labeling strategy.

Is Cinvanti interchangeable with fosaprepitant?

They are both injectable aprepitant-related products, but they are not automatically identical products. Formulation, administration, labeling, handling, and institutional formulary decisions determine practical substitution.

Does aprepitant have a biosimilar market?

No. Aprepitant is a small-molecule drug. Competition proceeds through generic drug applications rather than biosimilar applications.

References

1. Merck & Co., Inc. (2008). Annual report 2007. Merck & Co., Inc.

2. Merck & Co., Inc. (2016). Annual report 2015. Merck & Co., Inc.

3. Merck & Co., Inc. (2019). Annual report 2018. Merck & Co., Inc.

4. U.S. Food and Drug Administration. (2003). FDA approves Emend for prevention of chemotherapy-induced nausea and vomiting. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2017). Cinvanti approval letter and prescribing information. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

7. U.S. Patent and Trademark Office. (1997). U.S. Patent No. 5,691,336: Morpholine compounds and pharmaceutical compositions. U.S. Department of Commerce.